Reviva Pharmaceuticals Holdings (RVPH) Other Accumulated Expenses (2022 - 2026)
Reviva Pharmaceuticals Holdings (RVPH) posted Other Accumulated Expenses of $718407.0 for Q1 2026, down 9.25% sequentially from $791611.0 in Q4 2025, and up 48.78% YoY from $482864.0 in Q1 2025.
Reviva Pharmaceuticals Holdings (RVPH) Other Accumulated Expenses (2022 - 2026) Analysis & Trends
Reviva Pharmaceuticals Holdings has reported Other Accumulated Expenses for 5 years, with the latest figure at $718407.0 in Q1 2026.
- Quarterly Other Accumulated Expenses rose 48.78% year-over-year to $718407.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $718407.0 (up 48.78% YoY) and the FY2025 annual result came in at $791611.0, up 58.13% from the prior year.
- Other Accumulated Expenses retreated to $718407.0 in Q1 2026 per RVPH's latest filing, from $791611.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $922592.0 in Q2 2025 and troughed at $298699.0 in Q4 2022.
- A 5-year average of $545208.1 and a median of $482864.0 in 2025 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses advanced 25.0% in 2024, then jumped 107.15% in 2025.
- Over 5 years, Other Accumulated Expenses stood at $298699.0 in 2022, then soared by 34.08% to $400490.0 in 2023, then rose by 25.0% to $500616.0 in 2024, then soared by 58.13% to $791611.0 in 2025, then declined by 9.25% to $718407.0 in 2026.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $718407.0, $791611.0, and $630471.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Reviva Pharmaceuticals Holdings | 6.74 Mn | 6.74 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 247,174.00 |
| Mar 31, 2026 | 718,407.00 |
| Dec 31, 2025 | 791,611.00 |
| Sep 30, 2025 | 630,471.00 |
| Jun 30, 2025 | 922,592.00 |
| Mar 31, 2025 | 482,864.00 |
| Dec 31, 2024 | 500,616.00 |
| Sep 30, 2024 | 428,801.00 |
| Jun 30, 2024 | 445,371.00 |
| Mar 31, 2024 | 377,367.00 |
| Dec 31, 2023 | 400,490.00 |
| Dec 31, 2022 | 298,699.00 |